🏛️ Verified NIH Record • Updated 2026-05-27
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC (NCT06246110)
A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Eikon Therapeutics
🩺 Plain-English Summary (8th-Grade Level)
This study is for patients with advanced/metastatic non-small cells lung cancer (NSCLC) who have not received any treatment through the vein for the advanced disease.
Who can join: Review the eligibility criteria below.
Location: Southern Cancer Care — Daphne, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (38 Sites)
Showing the first 25 of 38 sites.
- Southern Cancer Care — Daphne, Alabama
- Ironwood Cancer and Research Center — Chandler, Arizona
- California Cancer Care Associates for Research & Excellence — Fresno, California
- California Research Institute — Los Angeles, California
- University of Southern California, Norris Comprehensive Cancer Center — Los Angeles, California
- Providence St Joseph Hospital, Center for Cancer Prevention and Treatment — Orange, California
- Sutter Health Institute for Medical Research — Sacramento, California
- Rocky Mountain Cancer — Lone Tree, Colorado
- Bioresearch Partner — Hialeah, Florida
- Memorial Cancer Institute — Hollywood, Florida
- Mid-Florida Hematology and Oncology Center — Orange, Florida
- Orlando Health Cancer Institute — Orlando, Florida
- Atlanta Piedmont Hospital — Atlanta, Georgia
- Kaiser Permanente Hawaii — Honolulu, Hawaii
- Illinois Cancer Specialists — Niles, Illinois
- Accelacare of Duly — Tinley Park, Illinois
- Indiana University Cancer Center — Indianapolis, Indiana
- Health Midwest Oncology Associates of Kansas — Overland Park, Kansas
- Cancer Center of Kansas — Wichita, Kansas
- Medstar Franklin Square Cancer Center at Loch Raven Campus — Baltimore, Maryland
- Maryland Oncology — Columbia, Maryland
- Jersey Shore University Medical Center/Meridian Hematology & Oncology — Neptune City, New Jersey
- New York Cancer and Blood Specialists — Babylon, New York
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York
- Weil Cornell Medical Center — New York, New York
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in NSCLC
- Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy — Savannah, Georgia
- Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC — La Jolla, California
- A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care — Boston, Massachusetts
- Study of Oral MRT-2359 in Selected Cancer Patients — Scottsdale, Arizona
- Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations — Phoenix, Arizona
Explore by condition: All NSCLC clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.